RBD-6365

N/A

Report date: 2024/12/02 17:59:31
NME

Base Information

Drug NameRBD-6365
Drug Alias NameRBD6365RBD-6365SR065SR-065
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSuzhou Ribo Life Science Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Ruibo Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A